GlassScriptPhysician profile
Jeffrey L Maxcy
NPI 1891789384
$1,456.13
in general payments reported to CMS, 2019-2025
12 companies · $210 in 2025
The $210 reported for 2025 was more than what 75% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $94.70 · 2021: $97.23 · 2022: $120 · 2023: $325 · 2024: $220 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $308.79 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Sobi, INC | $220.30 | 2019-2023 | |
| Cranial Technologies, INC | $199.79 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $152.73 | 2020-2025 | Vaxelis, M-M-R II, Vaxneuvance |
| Sanofi Pasteur INC. | $146.62 | 2019-2025 | |
| Pfizer INC. | $100.92 | 2023-2025 | |
| Seqirus USA INC | $99.32 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
| Ultragenyx Pharmaceutical INC. | $94.37 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $62.81 | 2022-2024 | Flumist Quadrivalent |
| Phadia US INC. | $39.31 | 2023-2024 | Immunocap |
| Genzyme Corporation | $19.17 | 2024 | |
| Glenmark Therapeutics INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Maxcy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.